Decapeptides targeted at alpha-/beta-synuclein interaction sites
Decapeptides targeted at alpha-/beta-synuclein interaction sites has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 9, 2024: “β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein”.
1 paper studies it2 findingsUpdated
- 1 lab in 1 country
- Funders: Huazhong University of Science and Technology and 4 more
- Model organisms1
What did studies of Decapeptides targeted at alpha-/beta-synuclein interaction sites find?
2Studies of Decapeptides targeted at alpha-/beta-synuclein interaction sites measured 2 outcomes; the most studied are lifespan (1 study) and movement defects (1).
Lifespan
upin worms1
1 study
Lifespan
upin worms1
Decapeptides targeted at alpha-/beta-synuclein interaction sites extend lifespan in worms.
“Decapeptides targeted at the α-/β-synuclein interaction sites are rationally designed, which suppress the LSPS of α-synuclein, rescue the movement defects, and prolong the lifespan of C. elegans NL5901.”
Model organismsin C. elegans NL5901
β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein
Nature communications
Movement defects
upin worms1
1 study
Movement defects
upin worms1
Decapeptides targeted at alpha-/beta-synuclein interaction sites improve movement defects in worms.
“Decapeptides targeted at the α-/β-synuclein interaction sites are rationally designed, which suppress the LSPS of α-synuclein, rescue the movement defects, and prolong the lifespan of C. elegans NL5901.”
Model organismsin C. elegans NL5901
β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein
Nature communications